Mark Elliott Boulding sold $489k of PTCT
EXEC. VP AND CLO at PTC THERAPEUTICS, INC.. 6,347 shares at an average of $77.06, traded Jan 8, 2026, filed Jan 12, 2026.
Score components
- +15RoleOfficer
- +18Trade size$489k at market
- 0Share of holdings soldSold 5.4% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001578852-26-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 8, 2026 | SOpen-market sale Common Stock10b5-1 | -2,482 | $76.56 | $190k | 115,177 | Jan 12, 2026 |
| Jan 8, 2026 | SOpen-market sale Common Stock10b5-1 | -265 | $77.07 | $20k | 114,912 | Jan 12, 2026 |
| Jan 8, 2026 | SOpen-market sale Common Stock10b5-1 | -1,286 | $76.45 | $98k | 113,626 | Jan 12, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -1,521 | $77.46 | $118k | 112,105 | Jan 12, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -686 | $78.71 | $54k | 111,419 | Jan 12, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -107 | $79.52 | $8,509 | 111,312 | Jan 12, 2026 |
Related signals
Other insiders at PTC THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $158k 2,500 shares | -0% | |
| 6Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $133k 2,073 shares | -2% | |
| 27Weak | PTC THERAPEUTICS, INC. | Glenn Steele Jr Md Phd director | $782k 12,000 shares | -35% | |
| 28Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.3M 20,000 shares | -2% | |
| 20Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.4M 20,000 shares | -1% | |
| 36Weak | PTC THERAPEUTICS, INC. | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | $253k 3,989 shares | -59% | |
| 15Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $210k 3,019 shares | -3% | |
| 15Weak | PTC THERAPEUTICS, INC. | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | $216k 3,121 shares | -3% | |
| 4Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $409k 5,894 shares | -5% | |
| 11Weak | PTC THERAPEUTICS, INC. | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | $72k 940 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.